Figure 6.
Figure 6. CD4+CD25+ T cells cultured in the presence of rapamycin, but not CsA, are able to inhibit ongoing T-cell responses. Freshly isolated CD4+CD25+ T cells (2.5 × 104) were stimulated with 1 × 105 γ-irradiated (30 Gy) HLA-mismatched stimulator PBMCs and additional IL-2 and IL-15 in the absence or presence of CsA (400 ng/mL) and rapamycin (100 nM). Cells were harvested at day 7, washed 3 times, and rested. At day 10, the cells were examined for suppressor function in suppression coculture assays. ExpTREGs derived from control (untreated), CsA-treated, and rapamycin-treated cultures (x axis) were cocultured from day 0 (T = 0) () or day 2 (T = 2) (▪) of MLR at a suppressor-to-effector ratio of 1:16 using 5 × 104 responder CD4+CD25- effector T cells and 5 × 104 γ-irradiated (30 Gy) stimulator PBMCs. Proliferation at day 5 of culture was measured by 3H-thymidine incorporation and is depicted as a percentage of inhibition on the y axis. A representative experiment is shown. *P < .05 for difference between groups.

CD4+CD25+ T cells cultured in the presence of rapamycin, but not CsA, are able to inhibit ongoing T-cell responses. Freshly isolated CD4+CD25+ T cells (2.5 × 104) were stimulated with 1 × 105 γ-irradiated (30 Gy) HLA-mismatched stimulator PBMCs and additional IL-2 and IL-15 in the absence or presence of CsA (400 ng/mL) and rapamycin (100 nM). Cells were harvested at day 7, washed 3 times, and rested. At day 10, the cells were examined for suppressor function in suppression coculture assays. ExpTREGs derived from control (untreated), CsA-treated, and rapamycin-treated cultures (x axis) were cocultured from day 0 (T = 0) () or day 2 (T = 2) (▪) of MLR at a suppressor-to-effector ratio of 1:16 using 5 × 104 responder CD4+CD25- effector T cells and 5 × 104 γ-irradiated (30 Gy) stimulator PBMCs. Proliferation at day 5 of culture was measured by 3H-thymidine incorporation and is depicted as a percentage of inhibition on the y axis. A representative experiment is shown. *P < .05 for difference between groups.

Close Modal

or Create an Account

Close Modal
Close Modal